Gabapentin
Product Images NDC 66116-444

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66116-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Structural Formula (6fa84b06 4292 43c2 888e 3e62b4c19a3d 01)

Chemical structure of gabapentin, showing a cyclohexane ring with an aminomethyl group and a carboxymethyl group attached to adjacent carbon atoms.*

FDA Label Image

Figure 1. Weekly Mean Pain Score (observed Cases In Itt Population): Study 1 (6fa84b06 4292 43c2 888e 3e62b4c19a3d 02)

A line graph comparing mean pain score over eight weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores. Gabapentin consistently shows lower pain scores than placebo with statistically significant differences (p < 0.01) indicated at various points.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (6fa84b06 4292 43c2 888e 3e62b4c19a3d 03)

A line graph showing mean pain score over 7 weeks comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The graph highlights a 3-week dose titration period followed by a 4-week fixed dose period, indicating reduced pain scores with Gabapentin versus placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With &gt; 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (6fa84b06 4292 43c2 888e 3e62b4c19a3d 04)

A bar chart comparing the percentage of responders at endpoint between placebo (PBO) and different doses of gabapentin (GBP) across two studies. Study 1 shows PBO at 12% and GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients &gt; 12 Years Of Age With Partial Seizures (6fa84b06 4292 43c2 888e 3e62b4c19a3d 05)

A chart showing percentage differences plotted against daily doses in milligrams (600, 900, 1200, 1800 mg). The chart includes data points distinguished by patterns and colors for three study groups labeled as STUDY a, STUDY b, and STUDY c.*

FDA Label Image

Gabapentin 300mg Capsules (6fa84b06 4292 43c2 888e 3e62b4c19a3d 06)

Gabapentin Capsules, USP 300 mg label from MedVantx Inc. The label indicates a package of 60 capsules with storage instructions at 20°-25°C (68°-77°F). It includes a dosage note to see the package insert and fields for dose and frequency to be filled in. The label states Rx only, sample only, not for sale, and provides contact information for Teva Pharmaceuticals USA as manufacturer and MedVantx Inc. as distributor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.